Skip to content Skip to navigation

GSK and Verily Form Joint Venture to Develop Bioelectronic Medicines

August 1, 2016
by Heather Landi
| Reprints

U.K.-based pharmaceutical company GlaxoSmithKline (GSK) is forming a joint venture with Verily Life Sciences, which is owned by Google parent company Alphabet, to research, develop and commercialize bioelectronics medicines.

The companies announced this week the new venture, Galvani Bioelectronics. GSK will hold a 55 percent equity interest in the new jointly owned company and Verily, which was formerly Google Life Sciences, will hold 45 percent equity interest.

Galvani Bioelectronics will be headquartered in the U.K., with the parent companies contributing existing intellectual property rights and an investment of up to 540 million pounds ($715 million) over seven years, subject to successful completion of various discovery and development milestones, the companies stated in a press release.

Bioelectronic medicine is a relatively new field that aims to tackle a wide range of chronic diseases using miniature, implanted devices that can modify electrical signals that pass along nerves in the body, including irregular or altered impulses that occur in many illnesses, according to the press release. GSK has been active in this field since 2012 and the company is betting that certain chronic conditions such as arthritis, diabetes and asthma could potentially be treated using these devices.

The new company will bring together GSK’s drug discovery and development expertise and work in disease biology with Verily’s technical expertise in the miniaturization of low power electronics, device development, data analytics and software development for clinical applications, the companies said.

“Initial work will center on establishing clinical proofs of principle in inflammatory, metabolic and endocrine disorders, including type 2 diabetes, where substantial evidence already exists in animal models; and developing associated miniaturized, precision devices,” the companies stated.

Galvani Bioelectronics will initially employ around 30 scientists, engineers and clinicians, and will fund and integrate a broad range of collaborations with both parent companies, academia and other R&D companies.

Kris Famm, GSK’s vice president of bioelectronics R&D, has been appointed president of the new company. Famm has co-designed and led GSK’s work in bioelectronics and since 2012, scientists at GSK have been researching the potential of bioelectronic medicines. In that time, the company has established a global network of around 50 research collaborations and investing $50 million in a dedicated bioelectronics venture capital fund.

Galvani Bioelectronics is named after Luigi Aloisio Galvani, an 18th century Italian scientist, physician and philosopher, who was one of the first to explore the field of bioelectricity.




ONC National Coordinator Gets Live Look at Carequality Data Exchange

Officials from Carequality have stated that there are now more than 150,000 clinicians across 11,000 clinics and 500 hospitals live on its network. These participants are also able to share health data records with one another, regardless of technology vendor.

American Red Cross, Teladoc to Provide Telehealth Services to Disaster Victims

The American Red Cross announced a partnership with Teladoc to deliver remote medical care to communities in the United States that are significantly affected by disasters.

Report: The Business of Cybercrime in Healthcare is Growing

While stolen financial data still has a higher market value than stolen medical records, as financial data can be monetized faster, there are indications that there is ongoing development of a market for stolen medical data, according to an Intel Security McAfee Labs report.

Phishing Attack at Baystate Health Potentially Exposes Data of 13K Patients

A phishing scam at Baystate Health in Springfield, Mass. has potentially exposed the personal data of 13,000 patients, according to a privacy statement from the patient care organization and a report from MassLive.

New Use Cases Driving Growth in Health Data Exchange through Direct

In an update, DirectTrust reported significant growth in Direct exchange of health information and the number of trusted Direct addressed enabled to share personal health information (PHI) in the third quarter of 2016.

Insurers to CBO: Consider Private Insurers’ Data in Evaluations of Telemedicine

Eleven private insurers, including Aetna, Humana and Anthem, are urging the Congressional Budget Office (CBO) to consider the experience of commercial insurers when evaluating the impact of telemedicine coverage in Medicare.